29 / 60
27
PROGRAMME & EXHIBITION GUIDE |
POSTERS
Freedom from regional failure of contralateral neck with ipsilateral neck radiothe-
rapy for node and tonsil cancer
A. Raben (USA), T.U. Dan, C. Schneider, N. Hockstein, R. Witt
PO-083
The pharmacokinetic characteristics of nimorazole in head and neck cancer patients
treated in the DAHANCA-5 trial
M.A.H. Metwally (Denmark), J.A. Jansen, J. Overgaard
PO-084
Evaluation of the impact of the oral cavity contour on dose and constraint com-
pliance in head-and-neck IMRT
I. Prieto (Spain), S. Gomez-Tejedor, J.P. Marin, A.M. Perez
PO-085
IMRT in nasopharyngeal carcinoma - Single institution - Experience from a develo-
ping country
C. Kainickal, B. Azariah (India), R. Kumar, M. Rafi, A. Sudha, R. Rajeev, S. Bhasi,
R. Kunnambath
PO-086
Long-term outcome of 18F-FDG-PET-guided dose painting for head and neck
cancer: matched case-controlled study
D. Berwouts (Belgium), F. Duprez, A.M.L. Olteanu, W. De Gersem, T. Vercauteren,
T. Boterberg, P. Deron, K. Bonte, W. De Neve, I. Madani
PO-087
Chemoradiotherapy for poor/intermediate risk oropharyngeal carcinoma: First
results of the ArCHIMEDEs study
V. Harrop (United Kingdom), S. Meade, L. Wagstaff, J. Babrah, P. Gaunt, M. Robinson,
J. Cash
more,
H. Mehanna, A. Hartley, P. Sanghera
PO-088
Adaptive radiotherapy in head and neck cancer
Y. Yahsi (Turkey), A. Okumus, T.O. Gursoy, O. Zeybek, H.O. Kizilkaya
PO-089
Normal tissue complication probability based multicriteria optimised IMRT in head
and neck cancer radiotherapy
K. Wopken, R.G.J. Kierkels (The Netherlands), H.P. Bijl, J.A.L. Langendijk
PO-090
TPExtreme randomised trial: Docetaxel-Platinum(P)-Cetuximab(C) versus 5FU-
P-C in recurrent/metastatic HNSCC
J. Guigay (France), U. Keilholz, R. Mesia, N. Vintonenko, J. Bourhis, A. Auperin
PO-091
Phase II study of TPF and cetuximab+RT in locally advanced laryngeal/hypopha-
ryngeal carcinoma
F. Arias (Spain), I. Hernández, G. Asín, J. Contreras, E. Villar, A.M. Pérez, V. Casado,
T. Bonfill, R. Vera
PO-092